RESUMO
Tardive akathisia is a movement disorder characterized by internal restlessness with an uncontrollable urge to move, leading to repetitive movements. It is a common side effect of long-term treatment with dopamine D2 receptor antagonists. In the present study, we analyzed the FDA Adverse Event Reporting System and IBM MarketScan Research Database to find a drug that can be used concomitantly with dopamine D2 receptor antagonists and still reduce the risk of akathisia. Acetaminophen was determined to be the most effective akathisia-suppressing drug. In an experimental validation of the hypothesis, chronic treatment of rats with haloperidol caused akathisia symptoms, including increased stereotyped behavior and locomotor activity, and decreased immobility time. Acute treatment with acetaminophen significantly attenuated haloperidol-induced akathisia. In the ventral striata of these rats, acetaminophen prevented haloperidol-induced decrease in the number of c-Fos+ preproenkephalin+ neurons. These results suggest that acetaminophen is effective in suppressing tardive akathisia by activating indirect-pathway medium spiny neurons.
Assuntos
Acatisia Induzida por Medicamentos , Antipsicóticos , Animais , Ratos , Acatisia Induzida por Medicamentos/tratamento farmacológico , Acatisia Induzida por Medicamentos/etiologia , Acatisia Induzida por Medicamentos/prevenção & controle , Haloperidol/efeitos adversos , Dopamina , Acetaminofen/efeitos adversos , Agitação Psicomotora/etiologia , Agitação Psicomotora/complicações , Antagonistas dos Receptores de Dopamina D2 , Antipsicóticos/efeitos adversosRESUMO
BACKGROUND: Akathisia is a distressing extrapyramidal complication that follows the use of antipsychotic medications. Early treatment of neuroleptic-associated akathisia (NAA) is of great importance because it may lead to poor therapeutic response and ultimately treatment noncompliance. Considering the lack of adequate response of some patients to conventional treatments and the assumption that serotonin might be involved in the pathophysiology of the disease in addition to dopaminergic mechanisms, we aimed to evaluate the effectiveness of trazodone as an antidepressant agent with strong antagonistic effects on serotonin receptors in the treatment of akathisia. METHODS: In a double-blind clinical trial, 52 patients receiving antipsychotic medications who were diagnosed to have mild to severe NAA using Barnes Akathisia Rating Scale were treated with trazodone 50 mg daily for 5 days and compared with the placebo control group. RESULTS: Patients receiving trazodone did not show a significant difference compared with the control group in terms of the severity of akathisia symptoms until the third day of the study. In contrast, at the end of the fifth day, there was a significant improvement in objective (P = 0.01) and subjective (P = 0.001) symptoms of akathisia and the global clinical assessment of akathisia scale (P = 0.001). Moreover, there was no clear difference between trazodone and placebo group in terms of adverse effects. CONCLUSIONS: Considering the antagonistic effect of trazodone on postsynaptic 5-hydroxytryptamine2A receptors as a possible mechanism of efficacy of this agent in the treatment of NAA, this study suggests that trazodone might be an effective and relatively safe drug.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/efeitos adversos , Atividade Motora/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Trazodona/uso terapêutico , Adulto , Acatisia Induzida por Medicamentos/diagnóstico , Acatisia Induzida por Medicamentos/etiologia , Acatisia Induzida por Medicamentos/psicologia , Antidepressivos de Segunda Geração/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Recuperação de Função Fisiológica , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Índice de Gravidade de Doença , Fatores de Tempo , Trazodona/efeitos adversos , Resultado do TratamentoRESUMO
PURPOSE OF REVIEW: Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents. Outpatient management is not always effective, and intravenous migraine management may be necessary for headache treatment in the pediatric emergency department. Most current treatment is based on retrospective evidence and there is a lack of well-designed randomized double-blinded controlled pediatric studies. Intravenous drug treatment agents including intravenous fluids, prochlorperazine, diphenhydramine, metoclopramide, dexamethasone, magnesium, valproate and propofol, and dihydroergotamine are reviewed in this paper. RECENT FINDINGS: Nineteen studies were reviewed including one prospective randomized double-blind; one single-blinded randomized; one prospective; and one open-label, randomized clinical trial. Most studies were retrospective and the quality of the studies was limited. No definite conclusions can be drawn from the studies, but appropriate prospective trials between major pediatric headache institutions will move pediatric intravenous migraine management forward.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Antagonistas de Dopamina/uso terapêutico , Glucocorticoides/uso terapêutico , Hipnóticos e Sedativos/uso terapêutico , Transtornos de Enxaqueca/tratamento farmacológico , Administração Intravenosa , Adolescente , Acatisia Induzida por Medicamentos/tratamento farmacológico , Acatisia Induzida por Medicamentos/etiologia , Anestésicos Locais/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Doenças dos Gânglios da Base/induzido quimicamente , Doenças dos Gânglios da Base/tratamento farmacológico , Criança , Dexametasona/uso terapêutico , Di-Hidroergotamina/uso terapêutico , Difenidramina/uso terapêutico , Serviço Hospitalar de Emergência , Inibidores Enzimáticos/uso terapêutico , Hidratação , Hospitalização , Humanos , Cetorolaco/uso terapêutico , Lidocaína/uso terapêutico , Magnésio/uso terapêutico , Proclorperazina/uso terapêutico , Propofol/uso terapêutico , Ácido Valproico/uso terapêutico , Vasoconstritores/uso terapêuticoRESUMO
BACKGROUND: Some evidence suggests that off-label use of mirtazapine (15 mg) is effective in treatment of acute antipsychotic-associated akathisia (AAA). We analyzed whether a lower dose of mirtazapine (7.5 mg) maintained its antiakathisia properties while exhibiting better tolerability in patients with schizophrenia and mood disorders who developed acute AAA. METHODS: Medical charts were retrospectively evaluated for 12 patients with AAA. All scored at least 2 (mild akathisia) on the Barnes Akathisia Rating Scale (BARS) and were treated with mirtazapine (7.5 mg) for a mean of 10.3 days. RESULTS: There was a statistically significant decrease in the BARS subjective, distress, and global (P < 0.01 to P < 0.001), but not objective (P = 0.63), subscales. Five participants (41.6%) fulfilled the predefined criterion of response, a decrease of at least 2 points on the BARS global subscale. The positive antiakathisia effect of mirtazapine was observed predominantly in aripiprazole-treated patients. Mirtazapine (7.5 mg) was well tolerated, and no clinically significant adverse effects, primarily drowsiness or increased appetite, were reported. CONCLUSIONS: A large-scale controlled evaluation is warranted to substantiate clinical utility of off-label use of mirtazapine (7.5 mg) for patients with AAA.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/efeitos adversos , Transtornos Mentais/tratamento farmacológico , Mirtazapina/farmacologia , Avaliação de Resultados em Cuidados de Saúde , Antagonistas do Receptor 5-HT2 de Serotonina/farmacologia , Adulto , Acatisia Induzida por Medicamentos/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mirtazapina/administração & dosagem , Uso Off-Label , Antagonistas do Receptor 5-HT2 de Serotonina/administração & dosagem , Adulto JovemRESUMO
INTRODUCTION: Akathisia is a common and severely disabling medication-induced movement disorder. The condition is often missed, and patients suffer for a long time until diagnosed and managed properly. It is important to bring awareness to the clinicians for early detection and management of akathisia. METHODS: We reviewed a 4-year record of patients seen at a comprehensive cancer center for anxiety and restlessness. Patients diagnosed with akathisia and the medications causing akathisia were identified. Management of akathisia is discussed. RESULTS: The results showed that 4.7% of patients developed akathisia while taking antiemetic agents to control chemotherapy-induced nausea/vomiting. Early detection and management of akathisia resulted in quick recovery and reduced patients' suffering. CONCLUSION: Akathisia is an unpleasant feeling of motor restlessness with anxiety. Clinicians need to have a full understanding to identify the subtle difference between functional anxiety and akathisia.
Assuntos
Acatisia Induzida por Medicamentos/epidemiologia , Acatisia Induzida por Medicamentos/etiologia , Antieméticos/administração & dosagem , Antineoplásicos/efeitos adversos , Acatisia Induzida por Medicamentos/tratamento farmacológico , Antieméticos/uso terapêutico , Antineoplásicos/uso terapêutico , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Agitação Psicomotora , Vômito/induzido quimicamenteRESUMO
BACKGROUND: Chemical restraint is often required to control agitation induced by methamphetamine. Dexmedetomidine is an α-2 adrenergic receptor agonist with sedative, analgesic, and sympatholytic properties. Its use in the emergency department (ED) to control methamphetamine-induced agitation has not been reported. OBJECTIVE: To report two cases of methamphetamine-induced agitation successfully sedated with dexmedetomidine in the ED. CASE REPORT: The first case was a 42-year-old man with unstable emotion and violent behaviours after smoking methamphetamine. His agitation did not respond to a large cumulative dose of benzodiazepines (10mg of diazepam and 332mg of midazolam) administered over 48h and sedation was achieved with dexmedetomidine. The second case was a 38-year-old methamphetamine user with unstable emotion and recurrent episodes of agitation despite repeated doses of benzodiazepines, whose agitation was controlled with dexmedetomidine infusion. DISCUSSION: In both cases, dexmedetomidine apparently reduced the dose of benzodiazepines needed to achieve adequate sedation. Transient falls in blood pressure and slowing of the heart rate were noted, which resolved either spontaneously or after reducing the infusion rate without requiring drug treatment. CONCLUSION: Dexmedetomidine can be considered as an adjunct for chemical restraint when standard treatment fails to control the agitation induced by methamphetamine, but patient's hemodynamic state should be monitored closely during administration. Its efficacy and safety in the ED warrant further evaluation with prospective controlled trials.
Assuntos
Inibidores da Captação Adrenérgica/efeitos adversos , Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico , Sintomas Afetivos/tratamento farmacológico , Agressão , Acatisia Induzida por Medicamentos/tratamento farmacológico , Confusão/tratamento farmacológico , Dexmedetomidina/uso terapêutico , Metanfetamina/efeitos adversos , Adulto , Sintomas Afetivos/induzido quimicamente , Acatisia Induzida por Medicamentos/etiologia , Confusão/induzido quimicamente , Serviço Hospitalar de Emergência , Humanos , MasculinoRESUMO
The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg intraperitoneally) hyperlocomotion, in contrast to σ1-receptors agonist Afobazole (1.0 mg/kg, intraperitoneally) that did not inhibit ethanol-induced behavioral stimulation. Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation. These findings suggest that Selank can modulate the motivational effects of ethanol.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Ansiolíticos/farmacologia , Etanol/farmacologia , Oligopeptídeos/farmacologia , Agitação Psicomotora/tratamento farmacológico , Receptores Opioides/metabolismo , Acatisia Induzida por Medicamentos/fisiopatologia , Animais , Comportamento Animal , Benzimidazóis/farmacologia , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Endogâmicos DBA , Morfolinas/farmacologia , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Agitação Psicomotora/fisiopatologia , Receptores Opioides/agonistasRESUMO
Akathisia remains a prevalent, clinically significant, and therapeutically challenging adverse event associated with antipsychotic treatment. Compelling evidence supports therapeutic efficacy and clinical utility of agents with marked serotonin 2A receptor antagonism, primarily low-dose mirtazapine, as an effective and well-tolerated antiakathisia treatment.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Acatisia Induzida por Medicamentos/etiologia , Antipsicóticos/efeitos adversos , Antagonistas do Receptor 5-HT2 de Serotonina/farmacologia , HumanosRESUMO
Asenapine is indicated for the treatment of schizophrenia and manic episodes in bipolar disorder (BPD). There is a paucity of information on the effects of asenapine in animal models of BPD, but such work is essential to discover its scope of effects and its mechanisms of therapeutic action. This study evaluated the effects of asenapine in a validated test battery for manic-like behaviors in Black Swiss mice. Male Black Swiss mice received asenapine at 0.03, 0.1, and 0.3 mg/kg twice daily for 7 days and were tested for spontaneous activity, sweet solution preference, forced-swim test, social interaction, and amphetamine-induced hyperactivity. Asenapine treatment resulted in dose-dependent, clinically relevant plasma levels. Asenapine, at the 0.1 and 0.3 mg/kg doses, reduced activity, with the 0.3 mg/kg dose also resulting in increased time in the center of an open field, increased immobility in the forced-swim test, and reduced amphetamine-induced hyperactivity. Asenapine exerted no effects in the social interaction or sweet solution preference tests. The results suggest that asenapine exerts antimanic-like effects in some of the behavioral tests performed in Black Swiss mice. These data support the utilization of asenapine in the treatment of BPD.
Assuntos
Antimaníacos/farmacologia , Transtorno Bipolar/tratamento farmacológico , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Acatisia Induzida por Medicamentos/tratamento farmacológico , Anfetamina/farmacologia , Anedonia/efeitos dos fármacos , Animais , Antimaníacos/sangue , Antipsicóticos/sangue , Antipsicóticos/farmacologia , Comportamento Apetitivo/efeitos dos fármacos , Estimulantes do Sistema Nervoso Central/farmacologia , Dibenzocicloeptenos , Relação Dose-Resposta a Droga , Comportamento Exploratório/efeitos dos fármacos , Preferências Alimentares/efeitos dos fármacos , Compostos Heterocíclicos de 4 ou mais Anéis/sangue , Masculino , Camundongos , Modelos Animais , Atividade Motora/efeitos dos fármacos , Testes Neuropsicológicos , Sacarina/administração & dosagem , Comportamento SocialRESUMO
BACKGROUND: Greater attention to and management of anxiety and pain in pediatric patients signifies a healthy evolution in the care of children in emergency departments (EDs). Interventions to address such distress may involve unanticipated adverse effects. Midazolam, a benzodiazepine commonly administered to children for anxiolysis, may precipitate paradoxical agitation and delirium, a rare but alarming effect that warrants prompt identification and treatment. CASE REPORT: The case presented is that of a 4-year-old girl who received oral midazolam and developed a paradoxical reaction, which was reversed successfully with flumazenil. This is the first such case report in an ED involving a child. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians must stay abreast of the adverse and unintended effects of the treatments provided. The literature on benzodiazepine-induced paradoxical reactions is reviewed, and flumazenil as well as other treatment options and anxiolytic alternatives are presented.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Ansiolíticos/efeitos adversos , Antídotos/uso terapêutico , Flumazenil/uso terapêutico , Midazolam/efeitos adversos , Pré-Escolar , Delírio/induzido quimicamente , Delírio/tratamento farmacológico , Feminino , HumanosRESUMO
Akathisia is a common and distressing extrapyramidal side-effect, which usually results from the use of antipsychotic medication. Previous reviews and meta-analyses have demonstrated a lack of evidence for the effectiveness of treatment strategies, which are traditionally used against neuroleptic-induced akathisia (NIA), i.e. beta-blockers, anticholinergic agents and benzodiazepines. In the last fifteen years, randomized trials have studied the effect of drugs with antiserotonergic properties on NIA. We conducted a systematic review of randomized control trials and used meta-analytic methods to quantify the overall effect size. PubMed and the Cochrane libraries were searched for eligible trials. Six randomized controlled trials were found, five of which included a placebo control group and qualified for our meta-analysis. The overall effect size in the analysis is RR = 7.10 with 95% CI 3.08-16.40 (p < 0.0001). Our findings suggest that 5-HT(2A) antagonists are effective in the treatment of NIA.
Assuntos
Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/efeitos adversos , Antagonistas do Receptor 5-HT2 de Serotonina/uso terapêutico , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
BACKGROUND: Methamphetamine is a major drug of abuse with no effective pharmacotherapy available. Trace amine associated receptor 1 is implicated in cocaine addiction and represents a potential therapeutic target. However, the effects of trace amine associated receptor 1 agonists on addiction-related behavioral effects of methamphetamine are unknown. METHODS: This study examined the effects of a trace amine associated receptor 1 agonist RO5263397 on methamphetamine-induced behavioral sensitization, methamphetamine self-administration, cue- and methamphetamine-induced reinstatement of drug seeking, and cue-induced reinstatement of sucrose-seeking behaviors in rats. Male Sprague-Dawley rats were used to examine the effects of methamphetamine alone and in combination with the trace amine associated receptor 1 agonist RO5263397 (3.2-10mg/kg). RESULTS: RO5263397 dose-dependently attenuated the expression of behavioral sensitization to methamphetamine, reduced methamphetamine self-administration, and decreased both cue- and a priming dose of methamphetamine-induced reinstatement of drug-seeking behaviors. However, RO5263397 did not alter cue-induced reinstatement of sucrose-seeking behavior. CONCLUSIONS: Taken together, trace amine associated receptor 1 agonists attenuate some abuse-related behavioral effects of methamphetamine, strongly suggesting that drugs activating trace amine associated receptor 1 may be potentially useful for the treatment of methamphetamine addiction and warrant further studies.
Assuntos
Transtornos Relacionados ao Uso de Anfetaminas/tratamento farmacológico , Estimulantes do Sistema Nervoso Central/administração & dosagem , Metanfetamina/administração & dosagem , Oxazóis/farmacologia , Receptores Acoplados a Proteínas G/agonistas , Acatisia Induzida por Medicamentos/tratamento farmacológico , Acatisia Induzida por Medicamentos/fisiopatologia , Transtornos Relacionados ao Uso de Anfetaminas/fisiopatologia , Animais , Comportamento Aditivo/tratamento farmacológico , Comportamento Aditivo/fisiopatologia , Sinais (Psicologia) , Sacarose Alimentar/administração & dosagem , Relação Dose-Resposta a Droga , Comportamento de Procura de Droga/efeitos dos fármacos , Comportamento de Procura de Droga/fisiologia , Masculino , Ratos Sprague-Dawley , Receptores Acoplados a Proteínas G/metabolismo , AutoadministraçãoRESUMO
BACKGROUND: Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as buprenorphine. CASE REPORT: A case is reported of a buprenorphine withdrawal syndrome with predominant symptoms of restlessness that were resistant to clonidine and benzodiazepines. It was successfully treated with the dopamine agonist pramipexole. SCIENTIFIC SIGNIFICANCE: Dopamine receptor agonists may have a place in the treatment of restlessness associated with opioid withdrawal and may have value for the broader spectrum of opioid withdrawal symptoms.
Assuntos
Benzotiazóis/uso terapêutico , Buprenorfina/efeitos adversos , Agonistas de Dopamina/uso terapêutico , Agitação Psicomotora/tratamento farmacológico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Acatisia Induzida por Medicamentos/tratamento farmacológico , Humanos , Masculino , PramipexolRESUMO
OBJECTIVE: This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL). METHODS: This study was a 12-weeks, preliminary open-label trial. The subjects were 17 inpatients. Their extrapyramidal symptoms (EPS) were assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), Abnormal Involuntary Movement Scale (AIMS), and Barnes Akathisia Scale (BAS), and their cognitive function was assessed using the Brief Assessment Cognition in Schizophrenia: Japanese language version (BACS-J), and their clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity of illness scale (CGI-S) at the 0 and 12 weeks. RESULTS: The DIEPSS and BAS significantly improved after switching from risperidone to PAL. Furthermore, improvement was found on AIMS. The mean change from baseline in z-score of the digit sequencing task was significantly increased. All items on the PANSS and CGI-S were not significant; however, changes in some cognitive function were correlated with changes in EPS. CONCLUSIONS: The results of this study suggest the possibility that switching elderly patients from risperidone to PAL may have improved pre-existing EPS, and may also have helped improve working memory.
Assuntos
Antipsicóticos/uso terapêutico , Transtornos Cognitivos/tratamento farmacológico , Isoxazóis/uso terapêutico , Pirimidinas/uso terapêutico , Risperidona/uso terapêutico , Esquizofrenia/tratamento farmacológico , Idoso , Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/efeitos adversos , Transtornos Cognitivos/etiologia , Substituição de Medicamentos , Discinesia Induzida por Medicamentos/tratamento farmacológico , Feminino , Humanos , Isoxazóis/administração & dosagem , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Testes Neuropsicológicos/estatística & dados numéricos , Palmitato de Paliperidona , Escalas de Graduação Psiquiátrica , Pirimidinas/administração & dosagem , Risperidona/efeitos adversos , Esquizofrenia/complicações , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Importance: Antipsychotic-induced akathisia (AIA) occurs in 14% to 35% of patients treated with antipsychotics and is associated with increased suicide and decreased adherence in patients with schizophrenia. However, no comprehensive review and network meta-analysis has been conducted to compare the efficacy of treatments for AIA. Objective: To compare the efficacy associated with AIA treatments. Data Sources: Three databases (MEDLINE, Web of Science, and Google Scholar) were systematically searched by multiple researchers for double-blind randomized clinical trials (RCTs) comparing active drugs for the treatment of AIA with placebo or another treatment between May 30 and June 18, 2023. Study Selection: Selected studies were RCTs that compared adjunctive drugs for AIA vs placebo or adjunctive treatment in patients treated with antipsychotics fulfilling the criteria for akathisia, RCTs with sample size of 10 patients or more, only trials in which no additional drugs were administered during the study, and RCTs that used a validated akathisia score. Trials with missing data for the main outcome (akathisia score at the end points) were excluded. Data Extraction and Synthesis: Data extraction and synthesis were performed, estimating standardized mean differences (SMDs) through pairwise and network meta-analysis with a random-effects model. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed. Main Outcomes and Measures: The primary outcome was the severity of akathisia measured by a validated scale at the last available end point. Results: Fifteen trials involving 492 participants compared 10 treatments with placebo. Mirtazapine (15 mg/d for ≥5 days; SMD, -1.20; 95% CI, -1.83 to -0.58), biperiden (6 mg/d for ≥14 days; SMD, -1.01; 95% CI, -1.69 to -0.34), vitamin B6 (600-1200 mg/d for ≥5 days; SMD, -0.92; 95% CI, -1.57 to -0.26), trazodone (50 mg/d for ≥5 days; SMD, -0.84; 95% CI, -1.54 to -0.14), mianserin (15 mg/d for ≥5 days; SMD, -0.81; 95% CI, -1.44 to -0.19), and propranolol (20 mg/d for ≥6 days; SMD, -0.78; 95% CI, -1.35 to -0.22) were associated with greater efficacy than placebo, with low to moderate heterogeneity (I2 = 34.6%; 95% CI, 0.0%-71.1%). Cyproheptadine, clonazepam, zolmitriptan, and valproate did not yield significant effects. Eight trials were rated as having low risk of bias; 2, moderate risk; and 5, high risk. Sensitivity analyses generally confirmed the results for all drugs except for cyproheptadine and propranolol. No association between effect sizes and psychotic severity was found. Conclusions and Relevance: In this systematic review and network meta-analysis, mirtazapine, biperiden, and vitamin B6 were associated with the greatest efficacy for AIA, with vitamin B6 having the best efficacy and tolerance profile. Trazodone, mianserin, and propranolol appeared as effective alternatives with slightly less favorable efficacy and tolerance profiles. These findings should assist prescribers in selecting an appropriate medication for treating AIA.
Assuntos
Acatisia Induzida por Medicamentos , Antipsicóticos , Humanos , Antipsicóticos/efeitos adversos , Biperideno , Ciproeptadina , Galopamil , Mianserina , Mirtazapina/uso terapêutico , Metanálise em Rede , Propranolol , Ensaios Clínicos Controlados Aleatórios como Assunto , Trazodona , Vitamina B 6 , Acatisia Induzida por Medicamentos/tratamento farmacológicoAssuntos
Antagonistas Adrenérgicos beta/efeitos adversos , Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/efeitos adversos , Quimioterapia Combinada/efeitos adversos , Olanzapina/efeitos adversos , Propranolol/efeitos adversos , Esquizofrenia/tratamento farmacológico , Sonambulismo/induzido quimicamente , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
OBJECTIVES: The prevalence of akathisia is variably reported in the literature and its psychiatric impact is little studied. The aim of this study was to establish the prevalence, the associated factors, and the psychiatric impact of akathisia among patients undergoing antipsychotic treatment. METHODS: A cross-sectional descriptive study was carried out at the Department of Psychiatry A, at Razi Hospital, in Tunis. It included patients with psychosis, undergoing antipsychotic treatment, from June 2016 to February 2017. Akathisia was diagnosed according to the Barnes Akathisia Scale. RESULTS: The prevalence of akathisia was 19.5% (n = 24, schizophrenia/schizoaffective disorder, n = 20; bipolar disorder, n = 4). The delay between the diagnosis of the disease and the onset of akathisia was 7.1 ± 8.8 years. Among the sample of patients with akathisia, 20/24 were on monotherapy of which 14 on conventional antipsychotics and six on atypical antipsychotics. Patients with akathisia were on atypical (8/24), low-potency conventional (4/24), or high-potency conventional (17/24) antipsychotics. The average dose of antipsychotics in chlorpromazine equivalent was 2294.5 ± 3037.7 mg. After adjusting for confounders, the only factor significantly positively associated with the diagnosis of akathisia was the dose of antipsychotics prescribed ( P = 0.01). The following psychiatric manifestations were reported by patients with akathisia: dysphoria/irritability (16/23), anxiety (18/24), sadness (15/24), suicidal thoughts (11/24), heteroaggressivity (8/23), sleep disturbances (16/24), and suicidal attempts (9/24). CONCLUSIONS: Despite the high psychiatric and social burden of akathisia, it remains largely underdiagnosed and undertreated, because in part of its subjective component.
Assuntos
Antipsicóticos , Esquizofrenia , Acatisia Induzida por Medicamentos/tratamento farmacológico , Acatisia Induzida por Medicamentos/epidemiologia , Acatisia Induzida por Medicamentos/etiologia , Antipsicóticos/efeitos adversos , Estudos Transversais , Humanos , Prevalência , Agitação Psicomotora/tratamento farmacológico , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológicoRESUMO
GBL (gamma-butyro-lactone) is converted to Gamma hydroxyl butyrate (GHB) in the body. GBL and GHB are available in liquid form and powder form. Once categorised under "legal highs", these two are not associated with any dependence or withdrawal in animal studies. But there are case reports indicating their high dependence potential in humans. We here present a case of a 29 year old who came to the attention of psychiatric services with very bizarre presentation and needed a host of investigations and expert views from various medical disciplines. He was treated mainly symptomatically followed by a sudden dramatic recovery on the 11th day after presentation. GBL is getting popular as a recreational drug and its withdrawal should be seriously considered in the list of medical causes leading to Delirium.
Assuntos
4-Butirolactona/intoxicação , Delírio/induzido quimicamente , Drogas Ilícitas/intoxicação , Síndrome de Abstinência a Substâncias/diagnóstico , Adulto , Acatisia Induzida por Medicamentos/diagnóstico , Acatisia Induzida por Medicamentos/tratamento farmacológico , Antipsicóticos/administração & dosagem , Clorpromazina/administração & dosagem , Delírio/diagnóstico , Delírio/tratamento farmacológico , Alucinações/induzido quimicamente , Alucinações/diagnóstico , Alucinações/tratamento farmacológico , Haloperidol/administração & dosagem , Humanos , Hipnóticos e Sedativos/administração & dosagem , Lorazepam/administração & dosagem , Masculino , Síndrome de Abstinência a Substâncias/tratamento farmacológicoRESUMO
Akathisia is a syndrome characterized by the unpleasant sensation of "inner" restlessness that manifests itself in the inability of sitting still or not moving. Many types of medicaments can cause akathisia as an adverse event of their use and they include: antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances. We will present the case of a 50 year old patient, treated on two occasions for psychotic depression. During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time, which is very difficult to determine in everyday clinical practice. We can conclude that in this case, as in many others, akathisia as a possible adverse effect of psychopharmacs was very hard to identify. Therefore, it is necessary to have akathisia in mind when using certain medicaments, especially when combining several that use the same enzymatic system and consequently raise levels of at least one of them.